112 results about "Choroid membrane" patented technology

The invention relates to the technical field of medical image processing and artificial intelligence, and discloses an artificial intelligence-based retinochoroid disease course structure change monitoring system, which comprises an image acquisition unit, a feature extraction unit, a lesion segmentation unit and the like. The image acquisition unit acquires retina optical coherence tomography sequence image data and fundus color image data; the feature extraction unit extracts a retina choroidal structure feature tensor through a three-dimensional convolutional neural network; the lesion segmentation unit outputs a lesion area probability distribution diagram by using a U-Net segmentation network; the time sequence alignment unit is used for registering the multi-time-point images to generate a displacement change matrix; the dynamic analysis unit extracts related indexes; an abnormal scoring unit constructs a disease course progress score; the decision grading unit outputs disease course stage classification labels; the multi-modal fusion unit fuses the multi-modal features; the report generation unit generates a structured disease course monitoring report. And favorable support is provided for diagnosis and treatment of ophthalmic diseases and illness state tracking.

The invention belongs to the technical field of nano-drugs, and discloses a multifunctional nano-drug delivery system for treating neovascular eye diseases and a preparation method of the multifunctional nano-drug delivery system. The nano drug delivery system disclosed by the invention is a composite nano preparation which takes dendritic mesoporous silica nanoparticles as a carrier and co-loads cerium zirconium oxide nano enzyme and an anti-VEGF (vascular endothelial growth factor) drug, various active oxygen can be efficiently removed, oxygen is continuously released through catalytic decomposition of hydrogen peroxide, a retina hypoxia microenvironment is improved, and the retina hypoxia effect is improved. According to the present invention, the anti-VEGF drug delivery system can reduce the oxidative stress induced retinal pigment epithelial cell apoptosis rate, reduce the inflammatory reaction, and simultaneously achieve the slow release and the controlled release of the anti-VEGF drug, and the drug effect maintenance time can achieve more than 60 days, such that the multi-target synergistic treatment can be achieved through the synergistic regulation of the multiple pathological links such as oxygen deficit-oxidative stress-inflammation-angiogenesis, and the anti-VEGF drug delivery effect can be achieved. The choroidal neovascularization can be effectively inhibited by single intravitreal injection, and a new strategy of multi-target collaborative treatment is provided for neovascular macular degeneration and other eye diseases.

By constructing an age-related macular degeneration animal model, experimental results in multiple aspects of clinical examination (FFA and ERG), pathological detection (RPE-choroidal patch IB4 fluorescent staining) and the like prove that the rucotinib can be used for effectively treating age-related macular degeneration, especially wet age-related macular degeneration.

An image processing method performed by a processor includes: a step of acquiring a fundus image in which choroid blood vessels are visualized; a step of extracting choroid arteries in the fundus image acquired in the acquiring step by performing image processing on the fundus image; and a step of generating a fundus image in which the choroid arteries extracted in the extracting step are highlighted.

The present invention discloses a method for constructing a choroidal segmentation model for OCT images in combination with a priori masks and its application. The present invention includes data preprocessing, through cropping, adjusting the scale, and then cropping to unify the data size; then generating two-stage choroidal masks through annotation; to solve the problem of complex image background, a cascaded multi-stage segmentation network is designed. In the first stage, the part below the BM layer is segmented to remove the upper background interference, and the second stage is to finely segment the choroid; to solve the problem of uneven choroidal texture and blurred lower boundary, a multi-scale context aggregation module is designed; finally, to optimize the training process of the cascade network, an adaptive cross-stage feature fusion module is designed. The present invention fully utilizes the information of the optical coherence tomography image itself and can effectively capture the multi-scale information and contextual information of the image, thereby improving the choroidal segmentation effect of the optical coherence tomography image.

The application discloses an ophthalmic choroid burst hemorrhage principle teaching mold, a plurality of water injection holes are arranged on the upper portion of the mold on the choroid, a plurality of water injection pipes are arranged correspondingly to the water injection holes, the water outlets of the water injection pipes are communicated to the choroid and the retina through the water injection holes, the water inlets are gathered in the sclera external port for connecting with a syringe, so that the syringe is used to inject or suck out liquid, and choroid burst hemorrhage is simulated. The application also provides a use method of the mold. The ophthalmic choroid burst hemorrhage principle teaching mold and the use method thereof can simulate choroid burst hemorrhage caused by eye injury, intraocular surgery and the like, have strong simulation, can realize on-site operation, have strong intuitiveness, good visual communication effect, are easy to understand, are convenient to carry, are easy to use, and greatly improve the teaching effect.

The invention discloses a double-drug-loading cationic mixed micelle as well as a preparation method and application thereof, and belongs to the field of pharmaceutics. The micelle is composed of a cationic polymer PEI-stearamide (PSA), an amphiphilic polymer DSPE-PEG2000, a hydrophobic drug resveratrol (RES) and a hydrophilic drug catalase (CAT). The preparation method comprises the following steps: 1) synthesizing PSA; the preparation method comprises 1, dissolving RES, PSA and DSPE-PEG2000 in an organic phase, injecting the obtained solution into a water phase, and carrying out rotary evaporation to obtain RES-loaded micelle (RES / PSA-PEG), and 3, adding a CAT solution to the micelle solution in a dropwise manner to obtain co-loaded micelle (RES / PSA-PEG / CAT). The micelle can effectively penetrate a corneal barrier and target a retinal pigment epithelial layer and a choroidal membrane.Through eye drop administration, RES anti-oxidation and anti-inflammatory effects and CAT hydrogen peroxide removal effects can be synergistically exerted, and an AMD curative effect can be substantially enhanced.

The present invention relates to an apparatus (110) and a method (210) configured to determine a choroidal topography (218) on a region (114, 114') of the retina (116) of a human eye (117), and to the use of the apparatus (110) for determining the effect of at least one ophthalmic lens design on the choroidal topography (218). In this document, the device (110) includes: - at least two separate displays (122, 122'), each configured to provide retinal stimulation (112, 112'), thereby providing two independent retinal stimuli (112, 112'); - at least two optical transmission elements, including a first optical transmission element and a second optical transmission element, each configured to project at least one of the retinal stimulation (112, 112') or a phase map onto a region of the retina of a human eye, wherein the phase map includes a modified retinal stimulation; - a measuring device (142) for capturing a human eye by using reflected light received from a region (114, 114') on the retina (116) of the human eye (117). (117) Choroidal topography (218) on region (114, 114') of retina (116); - Optical filter (152) configured to separate reflected light received from region (114, 114') of retina (116) of human eye (117) from phase map of region (114, 114') of retina (116) of human eye (117), wherein the second optical transmission element is further configured to simultaneously project each of the at least two separate phase maps at different retinal eccentricities onto each of at least two separate regions (134, 134') of retina (116) of human eye (117), wherein these separate regions (134, 134') include peripheral region and foveal region of retina (116) of human eye (117).

An image processing method comprising acquiring a first fundus image obtained by photographing a fundus using first light having a first wavelength, and a second fundus image obtained by photographing the fundus using second light having a second wavelength that is shorter than the first wavelength; specifying, in the first fundus image, respective positions of retinal blood vessels appearing in the second fundus image; and generating a choroidal blood vessel image by processing the positions identified in the first fundus image.

This invention provides a method and device for refractive development assessment based on visual development prediction neural circuits, relating to the field of myopia management technology. The method includes: acquiring color retinal optical imaging signals and refractive ground state quantification values ​​of the subject; performing retinal stabilization preprocessing; extracting multi-level morphological features through a reentrant layered retinal choroid encoder; performing spatial feature aggregation gating on the extracted feature maps to obtain feature vectors; concatenating and integrating the feature vectors with the refractive ground state quantification values ​​to obtain fused feature vectors; constructing a fused feature vector sequence and inputting it into a refractive development dynamics internal model inferrer to generate a future multi-time-point refractive state prediction sequence; converting it into an interpretable refractive state numerical sequence; and providing risk warnings based on preset risk thresholds. This invention explicitly embeds physiological mechanisms prior into the model structure and parameter adaptive strategies, thereby maintaining the stability and interpretability of predictions even in a single medical visit scenario.

The invention belongs to the technical field of biological medicines, and relates to application of an FGF2 inhibitor in preparation of a medicine for treating retina and choroidal neovascular diseases. An oxygen-induced retinopathy (OIR) mouse model and a novel small molecule compound are used for researching related mechanisms in retinopathy neovascularization, and the treatment effect of the small molecule compound is evaluated. Results show that the Refi-10 disclosed by the invention can be used for treating vascular retinopathy by inhibiting FGF2 targets, and a replacement or supplement method of VEGF (vascular endothelial growth factor) inhibiting drugs is provided.

The application discloses a choroid neovascularization image segmentation method based on a hybrid convolutional network, first, collecting fundus OCT scan images and labeling, and forming a data set by using the labeled images; a deep space-time separation hybrid convolutional neural network fusing an attention mechanism is constructed, two-dimensional feature extraction is carried out by using two-dimensional convolution, then the two-dimensional feature extraction is extended to three-dimensional, and then three-dimensional attention deep space-time separation convolution is carried out, and the two-dimensional feature and the three-dimensional feature are aligned and fused; then the hybrid neural network model constructed is trained by using the data set; finally, the trained hybrid neural network model is used to segment choroid neovascularization from the fundus OCT scan images, and a segmentation result is obtained. Through the space-time attention mechanism, local features of the choroid neovascularization image are better extracted, and by using the deep space-time separation convolution, a dimension reduction operation is carried out on the input feature map, so that the calculation parameters can be effectively reduced, thereby reducing the network calculation amount, and the channel attention can be more effectively calculated.

A System / Method / Device for segmenting the choroid-scleral layer from an optical coherent tomography (OCT) volume scan. The present system uses a deep learning machine model based on a neural network that include multiple convolution layers, but no deconvolution layers. Rather, the present neural network is based on a novel architecture based on the discrete cosine transform.

The present invention relates to an apparatus (110) and a method (210) configured determining a choroidal topography (218) over a region (114, 114') on a retina (116) of an eye (117) of a person as well as to a use of the apparatus (110) for determining an effect of at least one ophthalmic lens design on the choroidal topography (218). Herein, the apparatus (110) comprises: - at least two individual displays (122, 122') each configured for providing a retinal stimulus (112, 112'), thereby providing two independent retinal stimuli (112, 112'); - at least two optical transfer elements, comprising a first optical transfer element and a second optical transfer element, each configured for projecting at least one of the retinal stimulus (112, 112') or a phase map to a region on a retina of an eye of a person, wherein the phase map comprises a modified retinal stimulus; - a measuring device (142) for capturing a choroidal topography (218) over the region (114, 114') on the retina (116) of the eye (117) of the person by using reflected light received from the region (114, 114') on the retina (116) of the eye (117) of the person; - an optical filter (152) configured for separating the reflected light received from the region (114, 114') on the retina (116) of the eye (117) of the person from the phase map projected to the region (114, 114') on the retina of the eye of the person, wherein the second optical transfer element is further configured for simultaneously projecting each of the at least two individual phase maps at a different retinal eccentricity to each of at least two separate regions (134, 134') on the retina (116) of the eye (117) of the person, wherein the separate regions (134, 134') comprise a peripheral region and a foveal region on the retina (116) of the eye (117) of the person.

The present invention addresses the problem of providing an inhibitor for retinochoroidal disorders, in particular, an inhibitor for retinochoroidal scar formation and retinochoroidal atrophy in an epiretinal, intraretinal or subretinal tissue. This problem can be solved by preparing an inhibitor for retinochoroidal disorders which comprises, as an active ingredient, (E)-4-(2-{3-[(1H-pyrazol-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-yl}vinyl)benzoic acid, an ester thereof or a salt of the same. The inhibitor for retinochoroidal disorders can inhibit collagen atrophy of retinal pigment epithelium cells, fibroblasts, glial cells and the like and thus inhibit retinochoroidal disorders.

To enable understanding of choroidal asymmetry. [Solution] In choroidal vascular images, the direction of blood vessel course is determined for each of several pairs of analysis points that are symmetrical with respect to the line connecting the macula and the optic nerve head. The asymmetry of each pair of analysis points is analyzed from the direction of blood vessel course of each analysis point, and the pair of analysis points with asymmetry is highlighted by enclosing them in a frame.

This image processing device executes processing that includes: acquiring a tomographic image in the depth direction including choroidal blood vessels and sclera; executing emphasis processing that emphasizes a physical quantity indicating a brightness change in the depth direction in the tomographic image with respect to a partial region of the tomographic image; deriving an image feature amount pertaining to the brightness change in the depth direction in the emphasized region; and determining, on the basis of the image feature amount, a site on the tomographic image in which the image feature amount exceeds a predetermined threshold as a boundary between the choroidal blood vessels and the sclera.

The application discloses a choroid layer and choroid blood vessel segmentation method, system and device, and relates to the technical field of image processing. The method comprises the following steps: acquiring a target OCT choroid image; preprocessing the target OCT choroid image to generate a target choroid dataset; inputting the target choroid dataset into a pre-trained ASPP-SE-U-Net network for prediction; the ASPP-SE-U-Net network comprises a choroid CNN model and a choroid blood vessel CNN model; the step of inputting the target choroid dataset into the pre-trained ASPP-SE-U-Net network for prediction comprises the following steps: generating a choroid segmentation prediction map according to the choroid CNN model, generating a choroid blood vessel segmentation prediction map according to the choroid blood vessel CNN model and the choroid segmentation prediction map, superimposing the choroid segmentation prediction map and the choroid blood vessel segmentation prediction map to generate a choroid layer and choroid blood vessel segmentation map. According to the application, the segmentation result is more accurate.

The present disclosure provides for one or more embodiments for treating retinal degenerative disorders in a subject by administering to the subject an effective amount of allogeneic mesenchymal stem cells to the subject's suprachoroidal area. Allogeneic mesenchymal stem cells, when used in the disclosed treatment regimen, may exhibit anti-inflammatory, immunomodulatory, anti-fibrotic, pro-vascular, and / or pro-regenerative processes. Thus, allogeneic mesenchymal stem cells may be understood to have the potential to target and treat multiple pathological targets implicated in retinal degenerative disorders, including retinal disorders characterized by drusen accumulation, some of which have inherited forms.

To provide an image processing method for analyzing choroidal blood vessels.SOLUTION: The method includes a step of acquiring an OCT image of a subject's eye by optical coherence tomography (OCT), a step of extracting a region other than a structure of the subject's eye in the OCT image, and a step of generating a first display screen in which position information on a scan position for acquiring the OCT image is superimposed on the region.SELECTED DRAWING: Figure 10

The invention belongs to the technical field of biological medicines, and particularly relates to application of emipril in preparation of a medicine for improving choroidal neovascularization related diseases. The invention aims to solve the problems of strong invasiveness and limited curative effect of the existing therapy. It is found that emipril can achieve differential regulation and control on a CD26 system in vivo, that is, the enzyme activity of CD26 in bone marrow is improved, the enzyme activity of CD26 in peripheral blood is reduced, the concentration gradient of stromal cell-derived factor-1 can be established between the bone marrow and the peripheral blood through differential regulation and control, and the concentration gradient of the stromal cell-derived factor-1 can be further improved. The bone marrow-derived cells are driven to homing to eye lesions and differentiate into repair cells, so that eye diseases are repaired or improved, meanwhile, the collection and migration of bone marrow-derived macrophages to CNV regions can be increased, and the anti-inflammatory effect is achieved. According to the application, an endogenous repair mechanism is activated through non-invasive administration, and a safer and more effective treatment method is provided for related eye diseases.

The present invention relates to a method of producing a population of activated innate lymphoid cells, the population of activated innate lymphoid cells obtainable thereby, and use thereof in preventing or treating a disease in a subject. The present invention finds particular utility in the production of activated innate lymphoid cells useful in the treatment of ocular diseases such as neovascular diseases of the choroid and / or the retina.

The invention discloses an atropine derivative and a preparation method and application thereof, and belongs to the technical field of medical preparations, the atropine derivative and a salt or a pharmaceutical composition thereof can be used as a ciliary muscle paralysis agent and / or a mydriasis agent; the choroid and sclera functions can be regulated and controlled by improving choroid microcirculation and sclera hypoxia environment, inhibiting an HIF-1alpha signal channel and directly targeting sclera fibroblasts to inhibit extracellular matrix generation and remodeling; the medicine is used for relieving muscae volitantes symptoms; amblyopia, lazy eye diseases or myopia can be relieved; for treating or preventing myopia; the traditional Chinese medicine composition has good maintenance time and treatment effect, can obviously reduce the use frequency and use amount, improves the use experience, and reduces the medicine use cost.

The present invention belongs to the field of tumor immunotherapy, and relates to a humanized anti-VEGF antibody Fab fragment. The present invention discloses nucleic acid sequences (including heavy / light chain variable regions) encoding said antibody fragment, and vectors, pharmaceutical compositions and kits containing said nucleic acid sequences. The anti-VEGF antibody Fab fragments disclosed in the present invention can specifically bind to VEGF with high affinity and block the binding of VEGF to the receptor VEGFR2, and also neutralize the proliferative effect of VEGF on HUVEC cells. Compared to the full-length antibody, antibodies in the form of Fab fragments have stronger penetrability and less toxic in terms of gastrointestinal perforation, hypertension and hemorrhage and do not stimulate the complement cascade reaction, thus reducing the risk of endophthalmitis and autoimmune inflammatory reactions. Thus it could be used in clinical treatment of ocular diseases characterized by choroidal neovascularization, including but not limited to age-related macular degeneration (AMD), diabetic macular edema (DME), retinal edema, degenerative myopia, choroidal neovascularization (CNV).

Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

The invention discloses a myopia prediction method and system based on multi-subject interaction, and relates to the technical field of medical health information, and the method comprises the steps: synchronously collecting multi-dimensional data through three types of heterogeneous subjects, namely ophthalmology diagnosis and treatment equipment, a wearable monitoring terminal and environment sensing equipment, building a multi-source heterogeneous data set with time-space alignment, and carrying out the multi-source heterogeneous data set; and extracting features of optic disc inclination, macular region choroid thickness, refractive fluctuation amplitude, short-distance eye using duration and sunlight intensity mean value from the multi-source heterogeneous data set. According to the method, by integrating ophthalmology diagnosis and treatment equipment, a wearable monitoring terminal and environment sensing equipment, synchronous collection and space-time alignment of multi-source heterogeneous data are achieved, and multi-dimensional features such as optic disc inclination, choroid thickness, refractive fluctuation, eye using duration and sunlight intensity are extracted; the comprehensive perception ability of the system on structure, physiology, behavior and environmental factors is improved, and the accuracy and dynamic prediction ability of pathological myopia risk identification are enhanced.

An apparatus and a method for determining a choroidal topography over a region on a retina of an eye of a person are disclosed. The apparatus is also used to determine an effect of an ophthalmic lens design on the choroidal topography. The apparatus includes two individual displays, two optical transfer elements, a measuring device, and an optical filter. The displays provide a retinal stimulus and the optical transfer elements projects the retinal stimulus or a phase map to a region on a retina. The phase map contains a modified retinal stimulus. The measuring device images a choroidal topography over the region on the retina by capturing reflected light. The optical filter separates the reflected light from the projected phase map. Further, the second optical transfer element simultaneously projects the individual phase maps at a different retinal eccentricity to a peripheral region and a foveal region of the retina.

The application discloses a kidney function risk information processing method based on OCTA features and clinical data, and relates to the technical field of artificial intelligence and intelligent medical treatment. Quantitative features such as blood vessel density, perfusion area, retinal thickness and choroidal vascular volume are extracted from multi-scale fundus OCTA images of a subject, and total feature data sets are constructed in combination with clinical biochemical indexes, so as to estimate glomerular filtration rate as an outcome index for binary classification labeling. Elastic network regression is adopted to screen key modeling features, and various machine learning models such as logistic regression, random forest and gradient boosting are simultaneously trained on a training set. After 5-fold cross-validation optimization, the optimal model is selected by comprehensively considering the receiver operating characteristic curve, the calibration curve and the decision curve. A nomogram is constructed based on the optimal model, and individual early kidney function decline risk probability numerical values and auxiliary reference information of the subject are outputted for reference of clinical doctors.

The present invention belongs to the technical field of polymer compounds, and specifically relates to the use of amphiphilic cationic modified mPEG-PCL nanoparticles in the preparation of drugs for treating retinal diseases. The technical problem to be solved by the present invention is the lack of nanomedicines for the treatment of retinal diseases. The technical solution of the present invention is the use of amphiphilic cationic modified mPEG-PCL nanoparticles in the preparation of drugs for treating eye diseases. The nanoparticles of the present invention have low cytotoxicity; can effectively inhibit the development of choroidal neovascularization; and can also be used as carriers for other eye disease-related drugs, enabling combined drug use and the treatment of various eye diseases.

A method and application for deep proteomics analysis of trace samples, which is used for high-depth and high-sensitivity proteomics analysis of the retinal pigment epithelium / choroid complex, and is also applicable to the deep proteomics testing of other trace samples, with wide applicability and flexibility. By systematically optimizing the LC-FAIMS-MS / MS parameters, the present invention overcomes the technical bottlenecks of low coverage of trace tissue proteome and poor quantitative stability, providing a highly sensitive solution for disease mechanism research and biomarker discovery. This method increases the number of protein identifications by 28%, expands the dynamic range to six orders of magnitude, improves the quantitative repeatability, and reduces the proportion of missing values to 6%; it can detect AMD-related low-abundance proteins and 10 cell type markers, helping with disease mechanism research.